Innoviva (INVA) Revenue Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147.00% |
| Dec 31, 2025 | 16.57% |
| Sep 30, 2025 | 3.98% |
| Jun 30, 2025 | 4.90% |
| Mar 31, 2025 | 2.41% |
| Dec 31, 2024 | -56.13% |
| Sep 30, 2024 | 6.36% |
| Jun 30, 2024 | 9.28% |
| Mar 31, 2024 | -55.47% |
| Dec 31, 2023 | -54.67% |
| Sep 30, 2023 | 1.75% |
| Jun 30, 2023 | -57.05% |
| Mar 31, 2023 | -56.71% |
| Dec 31, 2022 | -56.76% |
| Sep 30, 2022 | -51.54% |
| Jun 30, 2022 | -49.71% |
| Mar 31, 2022 | -50.23% |
| Dec 31, 2021 | -53.11% |
| Sep 30, 2021 | 24.05% |
| Jun 30, 2021 | -48.57% |
| Mar 31, 2021 | -46.44% |
| Dec 31, 2020 | -53.36% |
| Sep 30, 2020 | 45.58% |
| Jun 30, 2020 | 49.26% |
| Mar 31, 2020 | 62.72% |
| Dec 31, 2019 | 59.85% |
| Sep 30, 2019 | 131.03% |
| Jun 30, 2019 | 132.98% |
| Mar 31, 2019 | 134.39% |
| Dec 31, 2018 | 122.24% |
| Sep 30, 2018 | 171.91% |
| Jun 30, 2018 | 119.32% |
| Mar 31, 2018 | 108.73% |
| Dec 31, 2017 | 20.67% |
| Sep 30, 2017 | 102.46% |
| Jun 30, 2017 | 156.93% |
| Mar 31, 2017 | -20.29% |
| Dec 31, 2016 | 52.07% |
| Sep 30, 2016 | 38.95% |
| Jun 30, 2016 | 38.43% |
| Mar 31, 2016 | 30.73% |